Athersys Inc ATHX:NASDAQ

Last Price$0.18NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/25/22

Today's Change-0.02(7.83%)
Bid (Size)$0.19 (452)
Ask (Size)$0.19 (33)
Day Low / High$0.18 - 0.20
Volume90.9 K
 

View Biotechnology IndustryPeer Comparison as of 05/25/2022

 

Athersys Inc ( NASDAQ )

Price: $0.18
Change: -0.02 (7.83%)
Volume: 90.9 K
4:00PM ET 5/25/2022
 
 

Aspira Women's Health Inc ( NASDAQ )

Price: $0.42
Change: -0.03 (7.18%)
Volume: 751.5 K
4:00PM ET 5/25/2022
 
 

Larimar Therapeutics Inc ( NASDAQ )

Price: $2.74
Change: +0.04 (1.48%)
Volume: 42.5 K
4:00PM ET 5/25/2022
 
 

Catalyst Biosciences Inc ( NASDAQ )

Price: $1.42
Change: -0.01 (0.70%)
Volume: 129.2 K
4:44PM ET 5/25/2022
 
 

Avalon Globocare Corp ( NASDAQ )

Price: $0.50
Change: +0.003 (0.50%)
Volume: 100.00
3:51PM ET 5/25/2022
 

Read more news Recent News

Top Midday Decliners
2:03PM ET 5/23/2022 MT Newswires

Nymox Pharmaceutical (NYMX) said it received a refusal-to-file letter from the US Food and Drug Administration indicating the company needs to include...

Athersys Shares Drop After BofA Securities Downgrade
12:15PM ET 5/23/2022 MT Newswires

Athersys (ATHX) shares shed about 18% in Monday afternoon trading after BofA Securities downgraded the stock to underperform from neutral and slashed its...

--BofA Securities Downgrades Athersys to Underperform From Neutral, Adjusts Price Target to $0.25 From $1
9:08AM ET 5/23/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Athersys Shares Tumble Pre-Bell as MultiStem Study Misses Primary Endpoint
8:48AM ET 5/20/2022 MT Newswires

Athersys, Inc. (ATHX) shares are down more than 50% in premarket trading after the biotech company reported Friday that a study of its MultiStem ischemic...

View all Commentary and Analysis

Athersys: Focus On Stroke
9:40AM ET 5/04/2022 Seeking Alpha

Athersys - Hero Or Zero Opportunity
10:56AM ET 4/18/2022 Seeking Alpha

Athersys, Inc. (ATHX) CEO Daniel Camardo on Q4 2021 Results - Earnings Call Transcript
8:47PM ET 3/15/2022 Seeking Alpha

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
2:34PM ET 1/20/2022 Seeking Alpha

Company Profile

Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
Address3201 Carnegie Avenue
Cleveland, Ohio 44115-2634
Phone+1.216.431.9900
Number of Employees75
Recent SEC Filing05/12/20228-K
Chief Executive Officer & DirectorDaniel A. Camardo
President & Chief Operating OfficerWilliam B. J. Lehmann
Chief Financial & Accounting OfficerIvor MacLeod
Director, Chief Scientific Officer & Executive VPJohn J. Harrington

Company Highlights

Price Open$0.20
Previous Close$0.18
52 Week Range$0.18 - 1.81
Market Capitalization$46.6 M
Shares Outstanding252.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.35
Beta vs. S&P 500N/A
Revenue$24.3 M
Net Profit Margin-981.52%
Return on Equity-429.24%

Analyst Ratings as of 05/20/2022

Buy
2
Overweight
0
Hold
0
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset